Research programme: cancer vaccines - Sapvax

Drug Profile

Research programme: cancer vaccines - Sapvax

Alternative Names: SV-283; SV-638

Latest Information Update: 08 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Auckland
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malignant melanoma; Non-small cell lung cancer; Ovarian cancer
  • Research Lymphoma; Nasopharyngeal cancer

Most Recent Events

  • 07 Jul 2015 Sapvax plans a phase I trial for SV 283 for Cancer in New Zealand
  • 06 Jul 2015 Early research in Lymphoma and Nasopharyngeal cancer in New Zealand (unspecified route)
  • 06 Jul 2015 Preclinical trials in Non-small cell lung cancer, Ovarian cancer and Malignant melanoma in New Zealand (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top